Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors), Tubulin inhibitors, c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Preclinical | China | 18 Mar 2026 | |
| Colorectal Cancer | Preclinical | China | 18 Mar 2026 | |
| Lung Cancer | Preclinical | China | 18 Mar 2026 | |
| Vipoma | Preclinical | China | 18 Mar 2026 |






